摘要
目的探讨低分子肝素与尿激酶在急性心肌梗死患者中的联合应用价值。方法选择急性心肌梗死患者104例,随机将患者分为研究组和对照组。对照组患者给予常规治疗,研究组患者加用低分子量肝素钠注射液与注射用尿激酶的药物联合治疗方案,比较两组患者的临床治疗情况。结果研究组患者的显著进步率和总有效率较对照组患者均明显提高,分别达到63.46%和92.31%,而无效率则明显减少,仅为7.69%,并且均呈现出统计学差异(P<0.05)。结论低分子肝素联合尿激酶对急性心肌梗死患者临床治疗效果的改善具有极其重要的临床意义。
Objective To probe into clinical application value of low molecular weight heparin combined with urokinase in the treatment of acute myocardial infarction. Methods Selected acute myocardial infarction patients in our hospital. All the patients were divided into study group and the control group randomly. The patients in control group were treated with conventional therapy. The patients in the study group were treated with low molecular weight heparin sodium injection combined with injection with urokinase therapy. The clinical treatment situations of the patients in two groups were Compared and analysis. Results Compared with control group, patients in study group the progress rate and total effective rate were improved significantly, up to 63.46% and 92.31% respectively, the inefficiency rate was reduced significantly, only 7.69%, there were statistically significant （P〈 0.05）. Conclusion The low molecular weight heparin combined with urokinase has extremely important clinical implications for the improvement of clinical outcomes in patients with acute myocardial infarction.
出处
《当代医学》
2013年第32期148-149,共2页
Contemporary Medicine
关键词
低分子肝素
尿激酶
急性心肌梗死
Low molecular weight heparin
Urokinase
Acute myocardial infarction
